drugset / Trial / NCT04492033
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a Phase 1b/2 multi-center study to assess the safety, tolerability, pharmacokinetics of CTX-009 (ABL001) in combination with Irinotecan or Paclitaxel in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2020-06-22
- Primary completion
- 2024-01-08
- Completion
- 2025-01-09
Outcome
Outcome not reported
Stopped: “Change of Development Plan”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTX-009 | Unknown | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |